Literature DB >> 32259636

Exposure to growth hormone is associated with hepatic up-regulation of cPLA2α and COX.

Verónica G Piazza1, María E Matzkin2, Nadia S Cicconi1, Nadia V Muia1, Sofía Valquinta1, Gregorio J Mccallum1, Giannina P Micucci1, Thomas Freund1, Elsa Zotta3, Lorena González1, Mónica B Frungieri4, Yimin Fang5, Andrzej Bartke5, Ana I Sotelo1, Johanna G Miquet6.   

Abstract

Continuously elevated levels of growth hormone (GH) during life in mice are associated with hepatomegaly due to hepatocytes hypertrophy and hyperplasia, chronic liver inflammation, elevated levels of arachidonic acid (AA) at young ages and liver tumors development at old ages. In this work, the hepatic expression of enzymes involved in AA metabolism, cPLA2α, COX1 and COX2 enzymes, was evaluated in young and old GH-transgenic mice. Mice overexpressing GH exhibited higher hepatic expression of cPLA2α, COX1 and COX2 in comparison to controls at young and old ages and in both sexes. In old mice, when tumoral and non-tumoral tissue were compared, elevated expression of COX2 was observed in tumors. In contrast, exposure to continuous lower levels of hormone for a short period affected COX1 expression only in males. Considering the role of inflammation during liver tumorigenesis, these findings support a role of alterations in AA metabolism in GH-driven liver tumorigenesis.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cyclooxygenase; Growth hormone; Liver; Phospholipase A2

Mesh:

Substances:

Year:  2020        PMID: 32259636      PMCID: PMC7211091          DOI: 10.1016/j.mce.2020.110802

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  51 in total

Review 1.  Controversies in the risk of neoplasia in GH deficiency.

Authors:  Sandra Pekic; Marko Stojanovic; Vera Popovic
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-02-22       Impact factor: 4.690

Review 2.  Growth hormone and cancer: an update on progress.

Authors:  Jo K Perry; Dong-Xu Liu; Zheng-Sheng Wu; Tao Zhu; Peter E Lobie
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-08       Impact factor: 3.243

3.  High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice.

Authors:  K J Snibson; P S Bhathal; C L Hardy; M R Brandon; T E Adams
Journal:  Liver       Date:  1999-06

4.  The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility.

Authors:  J M Bugni; T M Poole; N R Drinkwater
Journal:  Carcinogenesis       Date:  2001-11       Impact factor: 4.944

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Jessica Zucman-Rossi; Eli Pikarsky; Bruno Sangro; Myron Schwartz; Morris Sherman; Gregory Gores
Journal:  Nat Rev Dis Primers       Date:  2016-04-14       Impact factor: 52.329

6.  PGE2 synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma.

Authors:  Shengbing Zang; Xiaojie Ma; Yanbin Wu; Wenwen Liu; Haili Cheng; Jiasi Li; Jingfeng Liu; Aimin Huang
Journal:  Hum Pathol       Date:  2017-03-12       Impact factor: 3.466

Review 7.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

Authors:  Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

Review 8.  Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.

Authors:  John J Kopchick; Edward O List; Bruce Kelder; Elahu S Gosney; Darlene E Berryman
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 9.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

10.  Growth hormone upregulates the pro-tumorigenic galectin 1 in mouse liver.

Authors:  María L Bacigalupo; Verónica G Piazza; Nadia S Cicconi; Pablo Carabias; Andrzej Bartke; Yimin Fang; Ana I Sotelo; Gabriel A Rabinovich; María F Troncoso; Johanna G Miquet
Journal:  Endocr Connect       Date:  2019-08-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.